Study on the Prediction and Diagnosis of Immune-Related Pneumonia

Study on the Prediction and Diagnosis of Immune-Related Pneumonia - Study on the Prediction and Diagnosis of Immune-Related Pneumonia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057532

Enrollment

800

Registered

2025-04-08

Start date

2024-10-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune-Related Pneumonia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Retrospective observational study: Patients diagnosed with malignant tumors at Hamamatsu University Hospital who started immune checkpoint inhibitor (ICI) therapy as part of routine clinical care between September 2014 and March 31, 2024. 2.Patients enrolled in one or more of the following studies: Clinical Features and Outcomes of Pneumonitis related Anti-Programmed Death-1 therapy in Non-Small Cell Lung Cancer Patients (Study No. 18-205) Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study (Study No. 19-037) Immune checkpoint inhibitor-associated pneumonitis in patients with thoracic malignancy: Multicenter prospective observational study (Study No. 19-049)

Exclusion criteria

Exclusion criteria: Patients (or their representatives) who have withdrawn or refused consent for the use of their information in this study. Patients who did not develop immune-related pneumonitis (irP) and received two or fewer courses of immune checkpoint inhibitors (ICI).

Design outcomes

Primary

Measure	Time frame
Identification of clinical factors associated with immune-related pneumonia.	—

Countries

Japan

Contacts

Public ContactShogo Nakai

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

41242192@hama-med.ac.jp053-435-2263

Outcome results